Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SRC | P12931 | 3/20 | 0.62 |
| ▸ | BRAF | P15056 | 3/20 | 0.62 |
| ▸ | KDR | P35968 | 3/20 | 0.62 |
| ▸ | MAPK14 | Q16539 | 9/20 | 0.52 |
| ▸ | MAPK13 | O15264 | 5/20 | 0.50 |
| ▸ | MAPK12 | P53778 | 5/20 | 0.50 |
| ▸ | MAPK11 | Q15759 | 5/20 | 0.50 |
| ▸ | GCGR | P47871 | 2/20 | 0.50 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.50 |
| ▸ | FLT3 | P36888 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | USP2 | O75604 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6772178 | 0.89 | MAPK14 (0.54) | SRCBRAFKDRMAPK14MAPK13 | |
| SCHEMBL6773184 | 0.87 | MAPK14 (0.50) | SRCBRAFKDRMAPK14MAPK13 | |
| SCHEMBL6771597 | 0.87 | MAPK14 (0.58) | SRCBRAFKDRMAPK14MAPK13 | |
| SCHEMBL6773438 | 0.86 | MAPK14 (0.49) | SRCBRAFKDRMAPK14MAPK13 | |
| SCHEMBL6768792 | 0.86 | SRC (0.60) | SRCBRAFKDRMAPK14MAPK13 | |
| SCHEMBL6769879 | 0.85 | MAPK14 (0.47) | SRCBRAFKDRMAPK14MAPK13 | |
| SCHEMBL6769863 | 0.85 | MAPK14 (0.47) | SRCBRAFKDRMAPK14MAPK13 | |
| SCHEMBL6774360 | 0.84 | MAPK14 (0.49) | SRCBRAFKDRMAPK14MAPK13 | |
| SCHEMBL6772362 | 0.83 | MAPK14 (0.49) | SRCBRAFKDRMAPK14MAPK13 | |
| SCHEMBL6779368 | 0.83 | SRC (0.60) | SRCBRAFKDRMAPK14MAPK13 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-1505625-A | Triazole compounds useful in treating diseases associated with unwanted cytokine activity | — | 2004-06-16 | — | — | CN | claimed |
| US-6727364-B2 | ANTIINFLAMMATORY AGENTS | THE PROCTER & GAMBLE COMPANY | 2004-04-27 | — | — | US | claimed |
| US-20030013712-A1 | Triazole compounds useful in treating diseases associated with unwanted cytokine activity | PROCTER & GAMBLE COMPANY, THE | 2003-01-16 | — | — | US | claimed |
| US-6727364-B2 | ANTIINFLAMMATORY AGENTS | THE PROCTER & GAMBLE COMPANY | 2004-04-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030013712-A1 | Triazole compounds useful in treating diseases associated with unwanted cytokine activity | IL4, IL1A, IL2 | SRC 1940/4885BRAF 2861/4885KDR 1645/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.